12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CDX-011: Phase II data

In 26 evaluable patients from the Phase II portion of a Phase I/II trial, 1.88 mg/kg IV CDX-011 met the primary endpoint, which required >=5 of 25 (20%) patients in the Phase II portion to be progression-free at 12 weeks. Specifically, 9 of 26 (25%) patients were progression-free at 12 weeks. Of 32 patients from the entire trial receiving 1.88 mg/kg CDX-011, 4 (13%) achieved confirmed...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >